The consumerization of preventative care
How at-home diagnostics rewired the entry point to women's healthcare.
Executive summary
How at-home diagnostics rewired the entry point to women's healthcare. Executive Summary Preventive care is shifting from provider-centric, episodic care to consumer-centric, continuous care driven by three forces: (1) at-home diagnostics and wearables enabling continuous monitoring, (2) AI-driven interpretation turning raw data into actionable insights, and (3) consumer expectations for personalization and data ownership. OVUM reads this as a category signal for diagnostic access, testing infrastructure, and clinical workflow, with implications for product strategy, coverage design, and capital allocation.
Key findings
- Executive Summary Preventive care is shifting from provider-centric, episodic care to consumer-centric, continuous care driven by three forces: (1) at-home diagnostics and wearables enabling continuous monitoring, (2) AI-driven interpretation turning raw data into actionable insights, and (3) consumer expectations for personalization and data ownership.
- This consumerization creates a new preventive infrastructure layer between wellness and clinical care.
- Companies combining accessible diagnostics, AI insights, and clinical integration will capture disproportionate value.
- The market ($4-5B DTC testing, 15-20% annual growth) is fragmented, creating opportunities for specialized platforms addressing preventive care gaps.
Market implications
- Diagnostic gaps in women's health translate directly into misallocated care spend, giving payers a reason to fund earlier, more specific testing.
- Workflow fit — how a test integrates with OB, primary care, and specialty referral — will determine adoption more than analytical performance alone.
- Companion evidence linking a diagnostic to a treatment decision is the difference between a novelty and a reimbursed standard.
Interpretative layer
Professional access includes investor relevance, OVUM view, and category-level implications.
Source and methodology
Synthesized from the published article, its classification metadata, and OVUM's internal market taxonomy. Last indexed Apr 8, 2026.
Full analysis
Executive Summary Preventive care is shifting from provider-centric, episodic care to consumer-centric, continuous care driven by three forces: (1) at-home diagnostics and wearables enabling continuous monitoring, (2) AI-driven interpretation turning raw data into actionable insights, and (3) consumer expectations for personalization and data ownership. This consumerization creates a new preventive infrastructure layer between wellness and clinical care. Companies combining accessible diagnostics, AI insights, and clinical integration will capture disproportionate value. The market ($4-5B DTC testing, 15-20% annual growth) is fragmented, creating opportunities for specialized platforms addressing preventive care gaps.
Part 1: Continuous Monitoring Replaces Episodic Testing From Annual Physicals to Real-Time Biomarkers Traditional preventive care: annual physical with basic labs, reactive specialist visits, testing only when symptoms emerge. Continuous monitoring platforms enable real-time health tracking: Oura Ring ($200M+ funded): 24/7 sleep, HRV, temperature monitoring; detects illness 1-2 days before symptoms; used in fertility research Dexcom G7 / Abbott FreeStyle Libre: Continuous glucose monitoring; originally diabetes-focused, now expanding to gestational diabetes and PCOS Garmin / Apple Watch: Menstrual cycle tracking integrated with sleep and activity; enables cycle-health correlations Mira Fertility Monitor: At-home hormone testing (LH, E3G, PdG, FSH) with 99% accuracy; addresses irregular cycle monitoring gap From Provider-Ordered to Consumer-Initiated Testing Function Health: 100+ biomarkers in single test; membership model ($399-599); consumer owns data Everlywell: At-home test kits (hormones, fertility, heart health, STDs); 100M+ tests processed; retail distribution InsideTracker: Blood + DNA + wearable integration; proprietary "InnerAge" biological aging score Viome: Microbiome testing + AI nutrition recommendations; subscription model Teal Health: At-home cervical cancer screening (self-collection); addresses documented gap (75% of women skip preventive screenings due to access barriers) Advantage: Early detection before symptoms; lower intervention costs; consumer empowerment through data ownership.
Part 2: AI-Driven Interpretation at Scale Raw biomarker data requires interpretation. AI automates and personalizes this layer: ZOE ($118M funded): Microbiome + blood fat + CGM data → personalized nutrition; enables women to understand individual metabolic response January AI ($28.3M Series B): AI predicts glucose response to specific meals; relevant for PCOS, gestational diabetes, metabolic syndrome Floré by Sun Genomics ($21.1M Series A): Microbiome testing + AI-driven probiotic matching; addresses generic probiotic ineffectiveness Perelel ($37.7M + $27M growth): Life-stage nutrition for women (puberty → fertility → pregnancy → perimenopause → menopause); addresses women-specific gap Clue (FDA-cleared digital contraceptive): AI-driven cycle predictions; demonstrates regulatory-grade consumer tools Data Moats: Large longitudinal datasets create defensible advantages: - Flo Health: 100M+ downloads; AI predictions from massive dataset - Oura: 230,000+ patients with longitudinal sleep/HRV/temperature data - Viome: Large microbiome dataset enabling continuous refinement - Everlywell: 100M+ tests enabling population health insights
“Part 2: AI-Driven Interpretation at Scale Raw biomarker data requires interpretation.”
Part 3: Women's Health Consumerization From Reactive to Proactive Management Flo Health: 100M+ downloads; freemium cycle tracking + premium insights + B2B partnerships; expanding beyond cycles to holistic preventive health Natural Cycles: FDA-cleared contraceptive app; paid subscription; integrates with Oura for automated temperature input Ava Bracelet: Wearable + app for trying-to-conceive; multimodal biometrics (HRV, temperature, respiration, skin conductance) Stripes Beauty (Naomi Watts-founded): Menopause products + education; DTC e-commerce; destigmatizes menopause as lifestyle issue Wile ($3M seed): Perimenopause supplements + education; targets stress + hormones as integrated problem Teal Health: At-home cervical screening; B2B + B2C model; addresses preventive care access gap Integration Creates Network Effects Oura + InsideTracker: Wearable sleep/HRV + blood biomarkers + insights; enables lifestyle-biomarker correlation Apple Watch + Flo Health: Wearable cycle tracking + AI predictions; normalizes health tracking Dexcom + Nutrition Apps: Real-time glucose + personalized recommendations; enables food-glucose understanding Garmin + Fertility Apps: Wearable cycle tracking + fertility predictions; data-driven fertility awareness
Continue reading full analysis (5 more sections) →Collapse full analysis ↑
Part 4: Regulatory-Grade Consumer Tools Bridging Consumer Wellness and Clinical Care Clue Birth Control: FDA-cleared digital contraceptive; demonstrates consumer apps can achieve regulatory approval Natural Cycles: FDA-cleared fertility awareness app; enables evidence-based non-hormonal contraception Dexcom / FreeStyle Libre: Clinical-grade CGMs expanding into consumer wellness (metabolic health, PCOS, gestational diabetes) Teal Health: At-home cervical screening; removes barriers to preventive screening Challenge: Maintain clinical credibility while improving accessibility. Platforms achieving this balance capture disproportionate value.
Part 5: Business Model Shift to Recurring Revenue From One-Time Purchases to Recurring Revenue
Advantage: Improved unit economics, scale enablement, aligned incentives.
Part 6: Investment Implications Thesis 1: Consumerization Enables Venture Scale - Oura ($200M+), Flo Health (100M+ downloads), ZOE ($118M), Everlywell (100M+ tests), Maven Clinic (unicorn) - Consumer health platforms achieve venture-scale returns via accessibility + personalization + recurring revenue Thesis 2: Data Moats Are Defensible - Flo Health (100M+ users), Oura (230K+ patients), Viome (microbiome dataset), ZOE (multi-modal data), Everlywell (100M+ tests) - Large longitudinal datasets create defensible competitive advantages Thesis 3: Regulatory Approval Creates Moats - Clue Birth Control (FDA-cleared), Natural Cycles (FDA-cleared), Dexcom (clinical-grade), Teal Health (preventive screening) - Regulatory approval enables premium pricing and defensible positioning Thesis 4: Integration Creates Network Effects - Oura + InsideTracker, Apple Watch + Flo Health, Dexcom + Nutrition Apps, Garmin + Fertility Apps - Multiple integrated data sources increase value exponentially Thesis 5: Women's Health Consumerization Is Accelerating - Market: $4-5B (2024-2025) → $5-7B (2026); Flo Health (100M+ downloads), Natural Cycles (FDA-cleared), Stripes/Wile (celebrity-backed), Teal Health (preventive gap) - Moving from niche to mainstream Thesis 6: Multiple Business Models Succeed - Subscription, razor-razorblade, freemium, B2B2C, DTC e-commerce all achieving scale - Not a winner-take-all market
Conclusion Preventive care is shifting from provider-centric to consumer-centric through three forces: (1) at-home diagnostics and wearables, (2) AI-driven interpretation, (3) consumer expectations for personalization and data ownership. This creates a new preventive infrastructure layer. Companies combining accessible diagnostics, AI insights, and clinical integration capture disproportionate value. The market ($4-5B DTC testing, 15-20% growth) is fragmented, creating opportunities for specialized platforms addressing preventive care gaps.
Sources & citations →
References Oura Health. (2024). "Oura Ring and Health Tracking Data." Dexcom. (2024). "Continuous Glucose Monitoring Market." Everlywell. (2024). "At-Home Testing Market." InsideTracker. (2024). "Blood Biomarkers and Wearable Integration." Viome. (2024). "Microbiome Testing and Personalized Nutrition." ZOE. (2024). "Personalized Nutrition and Longevity Research." January AI. (2024). "Glucose Response Prediction." Flo Health. (2024). "Women's Health App Market." Natural Cycles. (2024). "FDA-Cleared Digital Contraception." Clue. (2024). "Cycle Tracking and Digital Contraception." Ava Bracelet. (2024). "Fertility Tracking Wearable." Stripes Beauty. (2024). "Menopause Products and Education." Wile. (2024). "Perimenopause Supplements." Teal Health. (2024). "At-Home Cervical Cancer Screening." Perelel. (2024). "Life-Stage Nutrition for Women."